UCB boosts bimekizumab's prospects in HS

Belgian drugmaker UCB (Euronext: UCB) has announced the first analyses of pooled data from two Phase III bimekizumab studies (BE HEARD I and BE HEARD II) in moderate to severe hidradenitis suppurativa (HS).

These analyses are among bimekizumab data in HS presented this week across three oral presentations and several posters at the 2023 European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany.

"Many patients treated with bimekizumab achieved high thresholds of response"Bimekizumab is not approved for use in HS by any regulatory authority worldwide, though the drug has won approvals to treat plaque psoriasis, psoriatic arthritis and axial spondyloarthritis, and is marketed under the brand name Bimzelx.